<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652661</url>
  </required_header>
  <id_info>
    <org_study_id>32466/11/20</org_study_id>
    <nct_id>NCT04652661</nct_id>
  </id_info>
  <brief_title>Intranasal Dexmedetomidine Versus Intranasal Midazolam for MRI In Pediatrics</brief_title>
  <official_title>Intranasal Dexmedetomidine Versus Intranasal Midazolam as Sole Sedative Agents for MRI In Pediatrics: A Randomized Double-Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increasing number of studies have reported the use of dexmedetomidine in clinical&#xD;
      practice. However, few studies have reported on the intranasal use of dexmedetomidine in&#xD;
      radiological procedures The aim of this work is to compare the efficacy and safety of&#xD;
      intranasal dexmedetomidine and intranasal midazolam in pediatrics undergoing MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective randomized double-blind clinical trial will be carried out on 60 children&#xD;
      undergoing elective MRI in Tanta University Hospitals.&#xD;
&#xD;
      Sixty children will be randomly allocated into two equal groups by computer-generated&#xD;
      sequence through sealed opaque envelopes:&#xD;
&#xD;
      Group D: 30 children will be sedated with 2 μg/kg intranasal DEX. Group M: 30 children will&#xD;
      be sedated with 0.3 mg/kg intranasal midazolam.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">June 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sixty children will be randomly allocated into two equal groups by computer generated sequence through sealed opaque envelopes:&#xD;
Group D: 30 children will be sedated with 2 μg/kg intranasal DEX. Group M: 30 children will be sedated with 0.3 mg/kg intranasal midazolam.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of successful sedation</measure>
    <time_frame>One hour</time_frame>
    <description>Successful sedation is defined as the time taken to achieve an MOAA/S score of 4 and is the time when the patients are calm and sedated and allow intravenous cannulation and MRI examination without crying or agitation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The onset time of sedation</measure>
    <time_frame>One hour</time_frame>
    <description>The onset time of sedation is defined as the time from drug administration to successful sedation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of Adverse effects</measure>
    <time_frame>One hour</time_frame>
    <description>The occurrences of adverse events will be recorded (e.g. bradycardia, a significant oxygen saturation decrease, severe arrhythmia or arrest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The degree of operator satisfaction</measure>
    <time_frame>One hour</time_frame>
    <description>MRI operator satisfaction before discharge using a 5- point score, with (0 = very dissatisfied, 1 = dissatisfied, 2 = neither satisfied nor dissatisfied, 3 = satisfied and 4 = very satisfied).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dexmedetomidine</condition>
  <condition>Midazolam</condition>
  <condition>MRI</condition>
  <condition>Pediatrics</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 children will be sedated with 2 μg/kg intranasal dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 children will be sedated with 0.3 mg/kg intranasal midazolam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>30 children will be sedated with 2 μg/kg intranasal DEX.</description>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>30 children will be sedated with 0.3 mg/kg intranasal midazolam.</description>
    <arm_group_label>Midazolam Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Aged from 2 to 8 years Both sexes ASA physical status I and II Elective MRI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient's guardian refusal.&#xD;
&#xD;
          2. Body mass index &gt;30 kg/m2&#xD;
&#xD;
          3. Known allergy to dexmedetomidine or midazolam.&#xD;
&#xD;
          4. Suspected difficult airway.&#xD;
&#xD;
          5. Upper respiratory tract infection&#xD;
&#xD;
          6. Anatomical structural deformity of the nasal cavity.&#xD;
&#xD;
          7. Severe liver or renal impairment.&#xD;
&#xD;
          8. Severe bradycardia or atrioventricular block above II degree type 2.&#xD;
&#xD;
          9. Administration of digoxin or beta blockers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tanta University Hospitals</name>
      <address>
        <city>Tanta</city>
        <state>ElGharbiaa</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taysser M Abdelraheem, MD</last_name>
      <phone>+201007592691</phone>
      <email>taysser.abdelreheem@med.tanta.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Taysser Mahmoud Abdalraheem</investigator_full_name>
    <investigator_title>Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will be provided with a reasonable request from authors</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

